ALDH1A1 and neoplasm: The authors’ ongoing study shows that an ALDH 1A1+1A3 peptide-DC vaccine elicits significantly stronger T cell and B cell immune responses against the tumor, compared with an ALDH1A1 or ALDH1A3 peptide-DC vaccine alone.